Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-223-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-223-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"The draft report does a good job of continuing the work carried out in the previous parliamentary term. The Commission proposal avoids giving specific definitions, despite the many recommendations. This kind of approach may lead to incomplete or unenforceable protection for patients who are consumers of medicinal products. That is why I welcome Amendment 120, which makes the Commission's proposal much less ambiguous. Particularly useful is the definition of a ‘falsified medicinal product’. The proposed text regarding ‘supply chains’ is also excellent, and if approved would strengthen the right of patients to protection. I consider the implementation of Recital 5c of Amendment 120, enabling the enforcement and monitoring of compliance with EU rules, to be imperative. The amendment brings EU regulations into line with the findings of the Court of Justice. In this context, the proposed text also allows Member States to take their own action in support of greater consumer protection."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples